NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board
January 13, 2022
Ryan Allway January 13th, 2022 Psychedelics Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced... Read more
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Biotechnology November 24, 2021
Ryan Allway November 24th, 2021 Psychedelics MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has... Read more
